Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-05-17
2005-05-17
Andres, Janet (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S449000, C536S026400, C549S510000
Reexamination Certificate
active
06894033
ABSTRACT:
Pharmaceutical compositions for treating viral, proliferative and inflammatory diseases are disclosed comprising an amount of pharmaceutically acceptable vitamin B12 compounds in combination with anti-viral, anti-proliferative and anti-inflammatory compounds. Vitamin B12 compounds are administered separately, simultaneously or in combination with anti-viral, anti-proliferative and/or anti-inflammatory compounds to provide an enhanced therapeutic effect for treating viral, proliferative and inflammatory diseases.
REFERENCES:
patent: 5565558 (1996-10-01), McCully
patent: 5574018 (1996-11-01), Habberfield et al.
patent: 5716941 (1998-02-01), Rabinoff
patent: 5716946 (1998-02-01), DeLuca et al.
patent: 5837822 (1998-11-01), Gallatin et al.
patent: 5846526 (1998-12-01), Cummins
patent: 5858980 (1999-01-01), Weiner et al.
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 5948764 (1999-09-01), Gaur et al.
patent: 5958409 (1999-09-01), Turk et al.
patent: 6036957 (2000-03-01), Weiner et al.
patent: 6121249 (2000-09-01), Weissman et al.
patent: 6143866 (2000-11-01), Brewer et al.
patent: 6184223 (2001-02-01), Kahn et al.
patent: WO 9845327 (1998-10-01), None
patent: WO 9913904 (1999-03-01), None
patent: WO 9916791 (1999-04-01), None
patent: WO 0112170 (2001-02-01), None
patent: WO 0128592 (2001-04-01), None
Chang et al. Cancer, vol. 91, 2001, pp. 417-422.*
Viastos et al., Cancer, 2000, vol. 88(6), pp. 1417-1424.*
Choi et al., Nutrition Review, 1999, pp. 250-260.*
Deisenhammer, et al., “Bioavailability of Interferon-Beta-1B in MS Patients with without Neutralizing Antibodies”,Neurology,52(6), pp. 1239-1243 (1999).
Durelli, et al., “Chronic Systemic High-Dose Recombinant Interferon Alfa-2a Reduces Exacerbation Rate, MRI Signs of Disease Activity and Lymphocyte Interferon Gamma Production in Relapsing-Remitting Multiple Sclerosis”,Neuro,44 (3 Pt 1): 406-413, (1994).
Fine, et al., “A Phase I Trial of a New Recombinant Human Beta-Interferon (BF9015) For the Treatment of Patients with Recurrent Gliomas”,Clinical Cancer Research,3(3), pp. 1-7 (1997).
Hall, et al., “Hydroxycabalamin/Sodium Thiosulfate as a Cyanide Antidote”,J. of Emergency Medicine,5(2), pp. 115-121 (1987).
Ide, H. et al., “Clinical Usefulness of Intrathecal Injection of Methylcobalamin in Patients with Diabetic Neuropathy”,Clin. Ther.,9:183-187, (1987).
Johnson, et al., “Copolymer 1 Reductes Relapse Rate and Improves Disability in Relapsing-Remitting Multiple Sclerosis: Results of Phase III Mulicenter, Double-Blind, Placebo-Controlled Trial”,Neuro,45:1268-1276, (1995).
Johnson, et al., “Extended use of Glatiramer Acetate (Copaxone) is Well Tolerated and Maintains Its Clinical Effect on Multiple Sclerosis Relapse Rate and Degree of Disability”,Neuro,50:701-708, (1998).
Lott, et al., “Vitamin B12 and Hepatitis C: Molecular Biology and Human Pathology”,Mol. Biol. and Human Path.,Proceedings of National Academy of Sciences, 98(9), pp. 4916-4921 (2001).
Mastronardi, et al., “Demyelination in a Transgenic Mouse: A Model for Multiple Sclerosis”,J. Neuro. Res.,36:315-324, (1993).
Mattner, et al., “Inhibition of Th1 Development and Treatment of Chronic-Relapsing Experimental Allergic Encephalomyelitis by a Non-Dihydroxyvitamin D3”,European J. Immunol.,30:498-508, (2000).
Miller, et al., “Magnetic Resonance In Monitoring the Treatment of Multiple Sclerosis”,Ann. Neurol.,36:Supp:S91-4, (1994).
Myhr, et al., Interferon-alpha2a Reduces MRI Disease Activity in Relapsing-Remitting Multiple Sclerosis: Norweigian Study Group on Interferon-alpha in Multiple Schlerosis,Neuro,23:52(5):1049-1056, (1999).
Nataf, et al., “Dihydroxyvitamin D3 Exerts Regional Effects in the Central Nervous System During Experimental Allergic Encephalomyelitis”,J. Neuro Exp. Neuro,55:904-914, (1996).
Nishizawa, et al., “Effects of Methylcobalamin on the Proliferation of Androgen-Sensitive or Estrogen-Sensitive Malignant Cells in Culture and In Vivo”,International J. of Vitamin Nutrition Research,67(3), pp. 164-170 (1997).
Norvedt, et al., “Type I Interferons and the Quality of Life of Multiple Sclerosis Patients. Results from a Clinical Trial on Interferon alfa-2a”,Multiple Scler.,5:317-322, (1999).
O'Connor, et al., “A Phase 1 Study of Micellar Paclitaxel in the Treatment of Secondary Progressive Multiple Sclerosis”,Ann. Neurol,46:470, (1999).
Amit, et al., “Molecular Pathogenesis of Multiple Sclerosis”,J. Immunol,100:252-259, (1999).
Barron, K., et al., “Multiple Sclerosis”, Rakel, R., Ed. 1995, Conn's Current Gherapy, WB Saunders Company, USA, pp. 732-734.
Brod, SA, et al., “Combination Therapy will Glatiramer Acetate Copolymer-1 and a Type I Interferon (interferon-alpha) Does Not Improve Experimental Autoimmune Encephalomyelitis”,Annals of Neurology,47(1), pp. 127-131 (2000).
Cabrera-Gomez, et al., Alpha Interferon in the Treatment of Multiple Sclerosis. Update and Experience in Cuba,Rev. Neuro,28:849-858, (1999).
Cao, et al., “Inhibition of Experimental Allergic Encephalomyelitis in the Lewis Rat by Paclitaxel”,J. Neuroummunol.,108:103-111, (2000).
Chofflon, et al., “Recombinant Human Interferon Beta In Relapsing-Remitting Multiple Sclerosis: A Review of the Major Clinical Trials”,European J. Neur.,7:369, (2000).
Chou, et al., “Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors”,Advances in Enzyme Regulation,vol. 22, pp. 27-55 (1984).
Polman, et al., “Drug Treatment of Multiple Sclerosis”,BMJ,321:490-494, (2000).
Pouly, et al., “Multiple Sclerosis and the Central Nervous System Demyelination”,J. Autoimmu.,13:297-306, (1999).
Poydock, et al., “Inhibiting Effect of Vitamins C and B12 on the Mitotic Activity of Ascites Tumors”,Experimental and Cellular Biology,vol. 47, pp. 210-217 (1979).
Poydock, et al., “Mitogenic Inhibition and Effect of Survival of mice Bearing L1210 Leukemia Using a Combination of Dehydroascorbic Acid and Hydroxycobalamin”,Am. Journal of Clinical Oncology,8(3), pp. 266-269 (1985).
Rudick, et al., “Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Theraputics”,Arch. Neuro.,56:1079-1084, (1999).
Rudick, et al., “Drug Therapy: Management of Multiple Sclerosis”,NEJM,337:1604-1611, (1997).
Sakane, et al., “Effects of Methyl-B12 on the In Vitro Immune Functions of Human T Lymphocytyes”,J. of Clinical Immunology,2(2), pp. 101-109 (1982).
Shimizu, et al., “Experimental Study of Anti-tumor Effect of Methyl-B12”,Oncology,44(3), pp. 169-173 (1987).
Steinman, et al., “From Treatment of Experimental Allergic Encephalmyelitis to Clinical Trials in Multiple Sclerosis”,Immunol. Ser.,59:253-60, (1993).
Tamura, et al., “Immunomodulation by Vitamin B12: Augmentation of CD8+ T Lymphocytes and Natural Killer (NK) Cell Activity in Vitamin B12-Deficient Patients by Methyl-B12 Treatment”,Clinical and Experimental Immunology,116(1), pp. 28-32 (1999).
Tselis, et al., “Multiple Sclerosis: Therapeutic Update”,Arch. Neuro.,56:277-280, (1999).
Tsao, et al., “Cytotoxic Activity of Cobalamine Cultured Malignant and Nonmalignant Cells”,Pathobiology,vol. 58, pp. 292-296 (1990).
Watanabe, et al., “Ultra-high Dose of Methylcobalamin Promotes Nerve Regeneration in Experimental Acrylamide Neuropathy”,J. Neurol. Sci.,122:140-143, (1994).
Weinberg, et al., “Inhibition of Productive Human Immunodeficiency Virus-1 Infection by Cobalamins”,Blood,86(4), pp. 1281-1287 (1995).
Weinberg, et al., “Inhibition of HIV-1 Integrase and Integration of HIV-1 DNA Into Cellular DNA”,Biochem. Biophys. Res. Communications,246(2), pp. 393-397 (1998).
Weinstock-Guttman, et al.,
Cruz Tony
Pastrak Aleksandra
Andres Janet
Fish & Richardson P.C.
Transition Therapeutics Inc.
LandOfFree
Combination therapies using vitamin B12 and therapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapies using vitamin B12 and therapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapies using vitamin B12 and therapeutic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3418247